Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).
Data from the phase 2 TheraP trial showed that 177Lu-PSMA-617 induced comparable overall survival outcomes as cabazitaxel in patients with metastatic castration-resistant prostate cancer who progressed after receiving docetaxel.
Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.
